ScholarBank@NUS
metadata only
SAFETY, EFFICACY, AND IMMUNOGENICITY OF SARS-COV-2 MRNA VACCINES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Booster Effect of mRNA Vaccine on Antibody Response for SARS-CoV-2 After Complete Vaccination With Sinos#890084
- Systematic characterization of SARS-CoV-2 spike protein subunit trafficking and secretion reveals enhanced strategies for vaccine design and quantification.#446218
- SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine#1057705
- Nanobodies against the S2 region of the spike protein potently neutralize SARS-CoV-2 viruses and show resistance to virus escape#291337
- The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients#185593
Record · ID 334543
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive